{"title":"补阳还五汤联合奥氮平对缺血性脑卒中后血管性痴呆患者临床症状、神经功能及痴呆程度的影响","authors":"Limin Zhang, Di Wu, Nian Chen","doi":"10.4314/tjpr.v22i9.25","DOIUrl":null,"url":null,"abstract":"Purpose: To determine the efficacy and safety of Buyang Huanwu Decoction (BHD) + olanzapine in the treatment of vascular dementia (VD) after cerebral ischemic stroke (CIS).Methods: Ninety patients with VD after CIS were assigned to 2 groups: a conventional group treated with olanzapine, and a combination group given olanzapine + BHD. Traditional Chinese medicine (TCM) symptom score was evaluated in each group. Neurological function, degree of dementia, and activities of daily living (ADL) were evaluated using National Institute of Health Stroke Scale (NIHSS), Clinical Dementia Rating (CDR) scale, and ADL scale, respectively. Levels of inflammatory factors, oxidative stress, and neurotrophic factors in peripheral blood were also determined. Middle cerebral artery (MCA), anterior cerebral artery (ACA), posterior cerebral artery (PCA), and vertebral artery (VA) blood flow velocity (BFV) were assessed. Therapeutic effects and adverse reactions (ARs) were recorded as well.Results: The TCM symptom, NHSS, and CDR scores were decreased in the combination group, while ADL scores were increased (p < 0.05). Levels of hs-CRP, IL-6, and malondialdehyde (MDA) also decreased, while IL-10, GPx, SOD, NT3, MCA, ACA, PVA, and VA BFV, and BDNF levels increased (p < 0.05). Clinical effectiveness (CE) levels in the conventional and combination groups were 73.3 and 93.3 %, while the incidence of ARs were 11.11 and 6.7 %, respectively (p < 0.05).Conclusion: Olanzapine + BHD mitigates clinical symptoms, enhances neurological function, decreases the degree of dementia, and increases ADL in patients with vascular dementia after CIS. Moreover, it improves cerebral blood flow, and it is safe to use. An increase in sample size will be needed to compare the long-term efficacy of olanzapine alone, and that of its combination with BHD in the treatment of VD after CIS.","PeriodicalId":23347,"journal":{"name":"Tropical Journal of Pharmaceutical Research","volume":"52 1","pages":"0"},"PeriodicalIF":0.6000,"publicationDate":"2023-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Effect of combined use of Buyang Huanwu decoction and olanzapine on clinical symptoms, neurological function, and degree of dementia in patients with vascular dementia after cerebral ischemic stroke\",\"authors\":\"Limin Zhang, Di Wu, Nian Chen\",\"doi\":\"10.4314/tjpr.v22i9.25\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Purpose: To determine the efficacy and safety of Buyang Huanwu Decoction (BHD) + olanzapine in the treatment of vascular dementia (VD) after cerebral ischemic stroke (CIS).Methods: Ninety patients with VD after CIS were assigned to 2 groups: a conventional group treated with olanzapine, and a combination group given olanzapine + BHD. Traditional Chinese medicine (TCM) symptom score was evaluated in each group. Neurological function, degree of dementia, and activities of daily living (ADL) were evaluated using National Institute of Health Stroke Scale (NIHSS), Clinical Dementia Rating (CDR) scale, and ADL scale, respectively. Levels of inflammatory factors, oxidative stress, and neurotrophic factors in peripheral blood were also determined. Middle cerebral artery (MCA), anterior cerebral artery (ACA), posterior cerebral artery (PCA), and vertebral artery (VA) blood flow velocity (BFV) were assessed. Therapeutic effects and adverse reactions (ARs) were recorded as well.Results: The TCM symptom, NHSS, and CDR scores were decreased in the combination group, while ADL scores were increased (p < 0.05). Levels of hs-CRP, IL-6, and malondialdehyde (MDA) also decreased, while IL-10, GPx, SOD, NT3, MCA, ACA, PVA, and VA BFV, and BDNF levels increased (p < 0.05). Clinical effectiveness (CE) levels in the conventional and combination groups were 73.3 and 93.3 %, while the incidence of ARs were 11.11 and 6.7 %, respectively (p < 0.05).Conclusion: Olanzapine + BHD mitigates clinical symptoms, enhances neurological function, decreases the degree of dementia, and increases ADL in patients with vascular dementia after CIS. Moreover, it improves cerebral blood flow, and it is safe to use. An increase in sample size will be needed to compare the long-term efficacy of olanzapine alone, and that of its combination with BHD in the treatment of VD after CIS.\",\"PeriodicalId\":23347,\"journal\":{\"name\":\"Tropical Journal of Pharmaceutical Research\",\"volume\":\"52 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.6000,\"publicationDate\":\"2023-10-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Tropical Journal of Pharmaceutical Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4314/tjpr.v22i9.25\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Tropical Journal of Pharmaceutical Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4314/tjpr.v22i9.25","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
Effect of combined use of Buyang Huanwu decoction and olanzapine on clinical symptoms, neurological function, and degree of dementia in patients with vascular dementia after cerebral ischemic stroke
Purpose: To determine the efficacy and safety of Buyang Huanwu Decoction (BHD) + olanzapine in the treatment of vascular dementia (VD) after cerebral ischemic stroke (CIS).Methods: Ninety patients with VD after CIS were assigned to 2 groups: a conventional group treated with olanzapine, and a combination group given olanzapine + BHD. Traditional Chinese medicine (TCM) symptom score was evaluated in each group. Neurological function, degree of dementia, and activities of daily living (ADL) were evaluated using National Institute of Health Stroke Scale (NIHSS), Clinical Dementia Rating (CDR) scale, and ADL scale, respectively. Levels of inflammatory factors, oxidative stress, and neurotrophic factors in peripheral blood were also determined. Middle cerebral artery (MCA), anterior cerebral artery (ACA), posterior cerebral artery (PCA), and vertebral artery (VA) blood flow velocity (BFV) were assessed. Therapeutic effects and adverse reactions (ARs) were recorded as well.Results: The TCM symptom, NHSS, and CDR scores were decreased in the combination group, while ADL scores were increased (p < 0.05). Levels of hs-CRP, IL-6, and malondialdehyde (MDA) also decreased, while IL-10, GPx, SOD, NT3, MCA, ACA, PVA, and VA BFV, and BDNF levels increased (p < 0.05). Clinical effectiveness (CE) levels in the conventional and combination groups were 73.3 and 93.3 %, while the incidence of ARs were 11.11 and 6.7 %, respectively (p < 0.05).Conclusion: Olanzapine + BHD mitigates clinical symptoms, enhances neurological function, decreases the degree of dementia, and increases ADL in patients with vascular dementia after CIS. Moreover, it improves cerebral blood flow, and it is safe to use. An increase in sample size will be needed to compare the long-term efficacy of olanzapine alone, and that of its combination with BHD in the treatment of VD after CIS.
期刊介绍:
We seek to encourage pharmaceutical and allied research of tropical and international relevance and to foster multidisciplinary research and collaboration among scientists, the pharmaceutical industry and the healthcare professionals.
We publish articles in pharmaceutical sciences and related disciplines (including biotechnology, cell and molecular biology, drug utilization including adverse drug events, medical and other life sciences, and related engineering fields). Although primarily devoted to original research papers, we welcome reviews on current topics of special interest and relevance.